Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia
Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia
复制标题
西达本胺联合化疗治疗难治性和复发性T淋巴细胞淋巴瘤/白血病
DOI：
10.1080/10428194.2019.1691195
复制
发表时间：
2019-11-21
影响因子：
2.6
通讯作者：
Yu, Li
中科院分区：
文献类型：
--
作者：
Guan, Wei;Jing, Yu;Yu, Li
Chidamide是一种新型组蛋白去乙酰化酶抑制剂，通过多种机制在t细胞肿瘤中发挥作用。17例难治性或复发性t细胞急性淋巴母细胞淋巴瘤/白血病（T-LBL/ALL）患者接受齐达胺联合化疗作为补救性治疗。分析历史资料，与化疗组比较。一个疗程后，齐达胺+化疗组的完全缓解率（CR）和总缓解率（ORR）均高于化疗组。奇达胺+化疗组的无进展生存期（PFS）优于化疗组。总生存期（OS）无差异。奇达胺+化疗组患者3/4级非血液学不良事件（bbb10 %）包括发热性中性粒细胞减少（64.7%）、药物性肝衰竭（17.6%）、纤维蛋白原降低（11.8%）、脓毒症（11.8%）、肺炎（11.8%）、口腔黏膜炎（11.8%）。本研究表明，Chidamide纳入方案可能是一种新的治疗策略，对于难治性或复发性T-LBL/ALL患者具有可接受的安全性，但需要进一步研究。
Abstract Chidamide, a novel histone deacetylase inhibitor, has exerted effects in T-cell tumors through various mechanisms. Seventeen patients with refractory or relapsed T-cell acute lymphoblastic lymphoma/leukemia (T-LBL/ALL) received Chidamide combined with chemotherapy as salvage treatment. Historical data was analyzed as comparison as chemotherapy group. Complete response (CR) rate and overall response rate (ORR) of Chidamide + chemotherapy group were higher than that of chemotherapy group after one course. Chidamide + chemotherapy group had a better progress-free survival (PFS) compared to chemotherapy group. No difference in overall survival (OS) was observed. Grade 3/4 nonhematological adverse events (>10%) of patients in Chidamide + chemotherapy group included febrile neutropenia (64.7%), drug-induced liver failure (17.6%), decreased fibrinogen (11.8%), sepsis (11.8%), pneumonitis (11.8%), and oral mucositis (11.8%). This study demonstrates that Chidamide included regimen may be a new treatment strategy with an acceptable safety profile for refractory or relapsed T-LBL/ALL patients but requires further investigation.